WO2007073919A2 - Procede de detection du cancer - Google Patents
Procede de detection du cancer Download PDFInfo
- Publication number
- WO2007073919A2 WO2007073919A2 PCT/EP2006/012330 EP2006012330W WO2007073919A2 WO 2007073919 A2 WO2007073919 A2 WO 2007073919A2 EP 2006012330 W EP2006012330 W EP 2006012330W WO 2007073919 A2 WO2007073919 A2 WO 2007073919A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkaloid
- compound
- quaternary
- alkaloid compound
- individual
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000001514 detection method Methods 0.000 title abstract description 7
- 229930013930 alkaloid Natural products 0.000 claims abstract description 74
- -1 alkaloid compound Chemical class 0.000 claims abstract description 62
- 238000011200 topical administration Methods 0.000 claims abstract description 18
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- 239000008280 blood Substances 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000005259 measurement Methods 0.000 claims abstract description 4
- 238000002189 fluorescence spectrum Methods 0.000 claims abstract description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 13
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims description 13
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims description 12
- WWEICYMHWQAHOS-UHFFFAOYSA-N Protopin Natural products CN1CCc2cc3OCOc3cc2C(=O)CCc4cc5OCOc5cc14 WWEICYMHWQAHOS-UHFFFAOYSA-N 0.000 claims description 9
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 claims description 9
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 claims description 9
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- MADYLZJCRKUBIK-RYGJVYDSSA-N (+/-)-Homochelidonine Chemical compound C([C@@H]1O)C2=CC=3OCOC=3C=C2[C@@H]2[C@H]1C1=CC=C(OC)C(OC)=C1CN2C MADYLZJCRKUBIK-RYGJVYDSSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 241001233914 Chelidonium majus Species 0.000 claims description 6
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000005284 excitation Effects 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 239000006194 liquid suspension Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229940084560 sanguinarine Drugs 0.000 claims description 6
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- AGSOWAZSCZVVDU-UHFFFAOYSA-N Allocryptopin Natural products C1=C2C(=O)CC=3C=C(OC)C(OC)=CC=3CN(C)CCC2=CC2=C1OCO2 AGSOWAZSCZVVDU-UHFFFAOYSA-N 0.000 claims description 4
- VVBOWTYRWIESFW-UHFFFAOYSA-N Methoxychelidonine Natural products C1=C2OCOC2=C2CN(C)C3C(C=C4OCOC4=C4OC)=C4CC(O)C3C2=C1 VVBOWTYRWIESFW-UHFFFAOYSA-N 0.000 claims description 4
- UXYJCYXWJGAKQY-OAHLLOKOSA-N ac1lf4k6 Chemical compound C1C2=C3OCOC3=CC=C2C[C@H]2N1CCC1=C2C=C(OCO2)C2=C1 UXYJCYXWJGAKQY-OAHLLOKOSA-N 0.000 claims description 4
- HYBRYAPKQCZIAE-UHFFFAOYSA-N allocryptopine Chemical compound C1=C2CCN(C)CC3=C(OC)C(OC)=CC=C3CC(=O)C2=CC2=C1OCO2 HYBRYAPKQCZIAE-UHFFFAOYSA-N 0.000 claims description 4
- MADYLZJCRKUBIK-UHFFFAOYSA-N alpha-homochelidonine Natural products OC1CC2=CC=3OCOC=3C=C2C2C1C1=CC=C(OC)C(OC)=C1CN2C MADYLZJCRKUBIK-UHFFFAOYSA-N 0.000 claims description 4
- IOFIEYRGKAUECR-UHFFFAOYSA-N chelamidine Natural products OC1C(O)C2=CC=3OCOC=3C=C2C2C1C1=CC=C(OC)C(OC)=C1CN2C IOFIEYRGKAUECR-UHFFFAOYSA-N 0.000 claims description 4
- XELDZRKHHSSBOE-UHFFFAOYSA-N chelamine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)C(O)C2=CC2=C1OCO2 XELDZRKHHSSBOE-UHFFFAOYSA-N 0.000 claims description 4
- UPVAYLMWVRMHNE-UHFFFAOYSA-N oxychelidonine Natural products C1=C2OCOC2=C2C(=O)N(C)C3C4=CC(OCO5)=C5C=C4CC(O)C3C2=C1 UPVAYLMWVRMHNE-UHFFFAOYSA-N 0.000 claims description 4
- 229960001945 sparteine Drugs 0.000 claims description 4
- DEXCWVBNPJKCOQ-UHFFFAOYSA-N tetrahydropseudocoptisine Natural products C1=C2C3CC(C=C4OCOC4=C4)=C4CN3CCC2=CC2=C1OCO2 DEXCWVBNPJKCOQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000008365 aqueous carrier Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 14
- 239000012503 blood component Substances 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229940068560 greater celandine Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
- A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne un procédé permettant la détection du cancer chez un individu, être humain ou animal, qui consiste en l'administration topique d'un composé alcaloïde hydrosoluble qui s'accumule de façon sélective dans les cellules cancéreuses et/ou interagit avec des composants sanguins d'un patient cancéreux à une dose détectable par mesure de fluorescence suite à une irradiation UV; le procédé comprend également l'exposition dudit individu à une irradiation UV, la détermination de l'émission de fluorescence, la comparaison des caractéristiques d'émission de fluorescence avec les valeurs correspondantes obtenues pour les témoins en bonne santé et l'évaluation des différences au niveau des spectres d'émission de fluorescence. Dans ce procédé, une réduction significativement plus rapide de l'émission de fluorescence dudit individu, par rapport aux témoins en bonne santé, indique une élimination accrue dudit composé alcaloïde à partir du site d'administration topique, et dès lors la présence de cellules cancéreuses chez ledit individu. La présente invention concerne également un kit d'éléments nécessaires pour mener à bien ce procédé.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05028615 | 2005-12-28 | ||
| EP05028615.2 | 2005-12-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007073919A2 true WO2007073919A2 (fr) | 2007-07-05 |
| WO2007073919A3 WO2007073919A3 (fr) | 2007-11-22 |
Family
ID=38218335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2006/012330 WO2007073919A2 (fr) | 2005-12-28 | 2006-12-20 | Procede de detection du cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007073919A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014083145A1 (fr) * | 2012-11-30 | 2014-06-05 | Sicpa Holding Sa | Marquage de matière, matière marquée et procédé d'authentification ou de détermination de dilution |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036257A1 (fr) | 2000-11-03 | 2002-05-10 | Polymun Scientific Immunbiologische Forschung Gmbh | Procede et dispositif pour produire des vesicules lipidiques |
| WO2003041721A1 (fr) | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Processus de reaction d'alcaloides et utilisation des produits de reaction dans la preparation de medicaments |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3128018A1 (de) * | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze" |
| CA2444413A1 (fr) * | 2003-10-09 | 2005-04-09 | Thomas H. Pearce | Fluorescence induite par laser violet pour le diagnostic du cancer |
| WO2006053680A1 (fr) * | 2004-11-19 | 2006-05-26 | Nowicky Wassili | Procede permettant de diagnostiquer un cancer ex vivo |
-
2006
- 2006-12-20 WO PCT/EP2006/012330 patent/WO2007073919A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036257A1 (fr) | 2000-11-03 | 2002-05-10 | Polymun Scientific Immunbiologische Forschung Gmbh | Procede et dispositif pour produire des vesicules lipidiques |
| WO2003041721A1 (fr) | 2001-11-15 | 2003-05-22 | Nowicky Wassili | Processus de reaction d'alcaloides et utilisation des produits de reaction dans la preparation de medicaments |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014083145A1 (fr) * | 2012-11-30 | 2014-06-05 | Sicpa Holding Sa | Marquage de matière, matière marquée et procédé d'authentification ou de détermination de dilution |
| CN104838254A (zh) * | 2012-11-30 | 2015-08-12 | 锡克拜控股有限公司 | 材料的标记、被标记材料和验证方法或稀释的确定 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007073919A3 (fr) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat | |
| Tas et al. | In vitro release studies of chlorpheniramine maleate from gels prepared by different cellulose derivatives | |
| Prados et al. | A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma | |
| Kheirolomoom et al. | Copper− doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity | |
| US6410512B1 (en) | Inhibitors of proteasomal activity for stimulating hair growth | |
| US9839638B2 (en) | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy | |
| Friberg et al. | pH effects on the cellular uptake of four photosensitizing drugs evaluated for use in photodynamic therapy of cancer | |
| JP2001513760A (ja) | ミトコンドリアの保護方法及びそのための組成物 | |
| JP6245481B2 (ja) | 非侵襲的イメージングのための組成物および方法 | |
| Wenande et al. | Laser-assisted delivery of synergistic combination chemotherapy in in vivo skin | |
| Bellnier et al. | A preliminary pharmacokinetic study of intravenous Photofrin® in patients | |
| CA2512059A1 (fr) | Formules d'administration transdermique de medicaments comprenant des quantites optimales de vasodilatateurs | |
| WO2015192215A1 (fr) | Peptide contenant des nano-vésicules lipidiques de porphyrine | |
| Honzak et al. | Development of liposome encapsulated clindamycin for treatment of acne vulgaris | |
| Le Guen et al. | Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone | |
| Birngruber et al. | Cerebral open flow microperfusion (cOFM) an innovative interface to brain tissue | |
| JP2000512279A (ja) | テキサフィリンの膜取り込み | |
| Olesen et al. | Enhanced and sustained cutaneous delivery of vismodegib by ablative fractional laser and microemulsion formulation | |
| CN114588268B (zh) | 提高激活sting通路和抗肿瘤t细胞应答的方法 | |
| Pierce et al. | Cerebral microdialysis as a tool for assessing the delivery of chemotherapy in brain tumor patients | |
| Pentak et al. | The role of nanoparticles in the albumin-cytarabine and albumin-methotrexate interactions | |
| Atif et al. | Progesterone modulates diabetes/hyperglycemia-induced changes in the central nervous system and sciatic nerve | |
| WO2007073919A2 (fr) | Procede de detection du cancer | |
| Lee et al. | Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline | |
| Schernthaner et al. | Medetomidine/midazolam/ketamine anaesthesia in ferrets: effects on cardiorespiratory parameters and evaluation of plasma drug concentrations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06841071 Country of ref document: EP Kind code of ref document: A2 |